Engage Therapeutics

May 6, 2019

Engage Therapeutics Presents Data from Part 1, Open-label Run-in of StATES Phase 2b Study of Staccato® Alprazolam at 2019 American Academy of Neurology Annual Meeting

Eight (8) patients with predictable generalized or focal epileptic seizures treated with Staccato alprazolam  62.5 percent of patients respond with cessation of seizure activity within two […]
March 13, 2019

Engage Therapeutics to Present Phase 2b Open Label Run-in Data from StATES Trial of Staccato Alprazolam at 2019 American Academy of Neurology Annual Meeting

SUMMIT, N.J., March 11, 2019 /PRNewswire/ — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people who experience […]
February 11, 2019

How Engage Therapeutics Is Improving Life With Epilepsy

International Epilepsy Day is here! With individuals and organizations sharing stories of taking action, we thought we’d take the opportunity to reflect on what the team […]
December 3, 2018

Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion

On December, 3, 2018, Engage Therapeutics announced at the American Epilepsy Society’s Annual Meeting the successful completion of the open label portion of the StATES (Staccato […]